Antihypertensive treatment, adiponectin and cardiovascular risk

Journal of Human Hypertension

Volumn 21, Issue 1, 2007, Pages 8-11

  Karthikeyan, V J ^a   Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIHYPERTENSIVE AGENT; CANDESARTAN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; NIFEDIPINE; RILMENIDINE; TEMOCAPRIL; VALSARTAN; VASCULOTROPIN;

ADIPOSE TISSUE; ANTIHYPERTENSIVE THERAPY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL TRANSFORMATION; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; LIPID STORAGE; MITOSIS INHIBITION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADIPONECTIN; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 33845538114     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002113     Document Type: Note

References (22)

1. Kakar P, Lip GYH. Towards understanding the aetiology and pathophysiology of human hypertension: Where are we now? J Hum Hypertens 2006; 20(11): 833-836.
2. Jessani S, Watson T, Cappuccio FP, Lip GY. Prevention of cardiovascular disease in clinical practice: The Joint British Societies' (JBS 2) guidelines. J Hum Hypertens 2006; 20: 641-645.
3. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: A systematic review of cohort studies. Lancet 2006; 368: 666-678.
4. Patel JV, Lim HS, Hughes EA, Lip GY. Adiponectin and hypertension: A putative link between adipocyte function and atherosclerotic risk? J Hum Hypertens 2007; 21(1): 1-4 (this issue).
5. Nowak L, Adamczak M, Wiecek A. Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2005; 18: 1470-1475.
6. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
7. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-1301.
8. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocytederived macrophages. Circulation 2001; 103: 1057-1063.
9. Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004; 315: 264-271.
10. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767-2770.
11. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278: 2461-2468.
12. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: More than just another fat cell hormone? Diabetes Care 2003; 26: 2442-2450.
13. Ran J, Hirano T, Fukui T, Saito K, Kageyama H, Okada K et al. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: An implication for hypertension-related insulin resistance. Metabolism 2006; 55: 478-488.
14. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N et al. Blockade of the reninangiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
15. Tomiyama H, Motobe K, Zaydun G, Koji Y, Yambe M, Arai T et al. Insulin sensitivity and endothelial function in hypertension: A comparison of temocapril and candesartan. Am J Hypertens 2005; 18: 178-182.
16. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006; 117: 385-392.
17. Nowak L, Adamczak M, Wiecek A. Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2005; 18: 1470-1475.
18. Nomura S, Inami N, Kimura Y, Omoto S, Shouzu A, Nishikawa M et al. Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens 2007; 21(1): 38-44 (this issue).
19. Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T. Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2005; 115: 277-285.
20. Berkels R, Egink G, Marsen TA, Bartels H, Roesen R, Klaus W. Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension 2001; 37: 240-245.
21. Verhaar MC, Honing ML, van Dam T, Zwart M, Koomans HA, Kastelein JJ et al. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc Res 1999; 42: 752-760.
22. Kakar P, Lip GYH. Towards improving the clinical assessment and management of human hypertension: An overview from this Journal. J Hum Hypertens 2006; 20(12): 913-916.